E-ISSN: 1308-5263
Turk J Hematol. 2025; 42(3): 232-234 | DOI: 10.4274/tjh.galenos.2025.2025.0019
2The 920th Hospital of Joint Logistics Support Force, Department of Hematology, Yunnan, P.R. China
3Kunming Medical University, School of General Practitioners, Department of Hematology, Yunnan, P.R. China
4The First People’s Hospital of Yunnan Province, Department of Integrated Traditional Chinese Medicine and Western Medicine, Yunnan, P.R. China
Keywords: T-cell acute lymphoblastic leukemia, Consolidation, Daratumumab, Venetoclax, Azacitidine
2The 920th Hospital of Joint Logistics Support Force, Department of Hematology, Yunnan, P.R. China
3Kunming Medical University, School of General Practitioners, Department of Hematology, Yunnan, P.R. China
4The First People’s Hospital of Yunnan Province, Department of Integrated Traditional Chinese Medicine and Western Medicine, Yunnan, P.R. China
Anahtar Kelimeler: T-hücreli akut lenfoblastik lösemi, Pekiştirme, Daratumumab, Venetoklaks, Azasitidin
Daratumumab, Venetoclax, and Azacitidine in Combination with the HAA Regimen as Consolidation Chemotherapy for T-Cell Acute Lymphoblastic Leukemia with High CD38 Expression
Lin-sen Feng1, Hui-yuan Li4, Ai Tang3, Meng-li Xu2, San-bin Wang21The Sixth Affiliated Hospital, Kunming Medical University, Department of Hematology, Yunnan, P.R. China; The 920th Hospital of Joint Logistics Support Force, Department of Hematology, Yunnan, P.R. China; The People’s Hospital of Yuxi City, Department of Hematology, Yunnan, P.R. China; Kunming Medical University, School of General Practitioners, Department of Hematology, Yunnan, P.R. China2The 920th Hospital of Joint Logistics Support Force, Department of Hematology, Yunnan, P.R. China
3Kunming Medical University, School of General Practitioners, Department of Hematology, Yunnan, P.R. China
4The First People’s Hospital of Yunnan Province, Department of Integrated Traditional Chinese Medicine and Western Medicine, Yunnan, P.R. China
Keywords: T-cell acute lymphoblastic leukemia, Consolidation, Daratumumab, Venetoclax, Azacitidine
Yüksek CD38 ifadeli T-hücreli Akut Lenfoblastik Lösemide Pekistirme Kemoterapisi Olarak HAA Rejimiyle Kombine Daratumumab, Venetoklaks ve Azasitidin
Lin-sen Feng1, Hui-yuan Li4, Ai Tang3, Meng-li Xu2, San-bin Wang21The Sixth Affiliated Hospital, Kunming Medical University, Department of Hematology, Yunnan, P.R. China; The 920th Hospital of Joint Logistics Support Force, Department of Hematology, Yunnan, P.R. China; The People’s Hospital of Yuxi City, Department of Hematology, Yunnan, P.R. China; Kunming Medical University, School of General Practitioners, Department of Hematology, Yunnan, P.R. China2The 920th Hospital of Joint Logistics Support Force, Department of Hematology, Yunnan, P.R. China
3Kunming Medical University, School of General Practitioners, Department of Hematology, Yunnan, P.R. China
4The First People’s Hospital of Yunnan Province, Department of Integrated Traditional Chinese Medicine and Western Medicine, Yunnan, P.R. China
Anahtar Kelimeler: T-hücreli akut lenfoblastik lösemi, Pekiştirme, Daratumumab, Venetoklaks, Azasitidin
Corresponding Author: San-bin Wang, China
Manuscript Language: English
Manuscript Language: English
Copyright © 2025 Turkish Journal of Hematology